Omega (OHI) Q4 2025 Earnings Call Transcript

Omega Healthcare Investors reported Q4 AFFO of $0.80 per share and FAD of $0.76 per share, with revenue rising to $319 million from $279 million and net income increasing to $172 million. Management raised confidence in 2026 with AFFO guidance of $3.15-$3.25 per share, leverage down to 3.51x, and liquidity of $1.7 billion in undrawn revolver capacity plus a new $2 billion ATM program. Offset by the setup of Genesis bankruptcy exposure and some 2026 loan-repayment headwinds, the call was overall constructive, supported by $1.1 billion of 2025 capital deployment and expanding RIDEA/Sabra/Canada initiatives.

Analysis

The core takeaway is not simply that the balance sheet improved; it is that management is deliberately swapping duration and credit risk for operating risk in a way that should widen the dispersion between OHI and the lower-quality healthcare REITs over the next 12-24 months. The portfolio is now being priced more like a capital allocator than a pure rent collector, and that matters because the market will likely reward the recurring cash-generation story before it fully credits the optionality embedded in RIDEA, Sabra, and Canada. The near-term implication is that FFO/FAD growth should stay resilient even if some loan principal runs off, because redeployment is still happening at double-digit unlevered economics.

The hidden risk is timing: the 2026 guidance is implicitly carrying a meaningful amount of principal runoff and assumes redeployment into a market where underwriting discipline is intact. That makes the next two quarters a sequencing story, not a pure fundamentals story. If loan repayments come back faster than the company can re-place capital, reported growth will look choppier and the stock could de-rate despite no deterioration in credit. Conversely, if management keeps landing off-market deals at 10%+ and the SHOP/RIDEA book scales without a stumble, consensus is probably still underestimating the multi-year FAD inflection.

Genesis remains the key event risk, but it is increasingly a mark-to-model rather than a thesis-breaker unless the sale process slips again. The more important second-order effect is that the resolution could become a catalyst for a cleaner re-rating of the balance sheet and dividend durability, especially given the low-80s payout threshold commentary. On the other side, SBRA is being transformed from a customer into a strategic revenue engine; that reduces concentration risk in the long run but also ties more of OHI’s future growth to a single operating relationship that could become more important than the market is currently modeling.

Key Decisions for Investors

• Long OHI common for 6-12 months: buy on any post-earnings weakness, targeting a rerating as 2026 FAD growth proves out and Genesis uncertainty compresses; risk is a slow redeployment cycle and a flat dividend path.
• Pair trade: long OHI / short SBRA on a 3-6 month horizon if you want cleaner balance-sheet quality exposure; OHI has more self-help from capital recycling, while SBRA looks more dependent on execution of the operating-company tie-up.
• Sell downside into the Genesis overhang: consider OHI put spreads 6-9 months out if the market starts pricing a second delay in asset sale closure; the asymmetry is that bad headlines can hit sentiment quickly, but the eventual cash recovery limits fundamental damage.
• Long OHI vs. other healthcare REITs with weaker operator coverage: OHI’s 1.5x+ coverage and lower leverage make it the cleaner relative-value long if sector volatility returns.
• Avoid chasing the dividend trade alone: if OHI rallies hard before evidence of redeployed principal or RIDEA scaling, trim into strength because the valuation can outpace near-term cash-flow realization.